IBOV 166,376.43 ▼ 0.69% COLCAP 2,452.46 — — IPC MEX 68,713.60 ▼ 0.64% MERVAL 2,848,945 — — USD/BRL5.94▲ 0.13% USD/MXN19.06▼ 0.11% USD/CLP1,017▼ 0.02% USD/COP3,419▲ 1.86% USD/PEN3.44▼ 0.14% USD/ARS1,568▲ 0.20% USD/UYU40.61▲ 3.16% USD/PYG6,212▲ 2.34% USD/BOB11.64▲ 2.55% USD/DOP59.71▼ 0.48% USD/CRC441.73▲ 2.68% USD/GTQ7.64▲ 3.22% USD/HNL26.89▼ 0.14% USD/NIO36.62▲ 0.34% USD/VES913.46▼ 0.35% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.59▲ 2.60% USD/TTD6.70▲ 2.00% EUR/BRL6.54▲ 1.36% BRENT 89.48 ▼ 2.72% WTI 82.44 ▼ 0.93% IRON ORE 161.91 — — COPPER 5.54 ▼ 1.56% GOLD 3,576 ▼ 2.97% SILVER 42.21 ▼ 4.76% SOY 1,213 ▲ 0.41% CORN 450.75 ▲ 2.68% WHEAT 596.00 ▲ 3.07% COFFEE 271.80 ▼ 3.63% SUGAR 16.99 ▼ 0.99% ORANGE JUICE 131.95 ▲ 1.85% COTTON 79.55 ▲ 4.74% COCOA 5,230 ▲ 3.30% BEEF 223.00 ▲ 1.47% CATTLE 335.85 ▼ 0.34% LITHIUM 54.33 ▼ 2.23% PETR4 42.67 ▼ 1.16% VALE3 58.48 ▼ 0.88% ITUB4 40.07 ▼ 0.30% BBDC4 13.83 ▼ 1.78% ABEV3 16.08 ▲ 0.06% BBAS3 14.30 ▲ 1.27% B3SA3 14.28 ▼ 0.14% WEGE3 51.13 ▼ 0.49% PRIO3 60.20 ▼ 2.70% SUZB3 55.32 ▼ 0.50% RENT3 28.86 ▼ 2.00% AZZA3 14.63 ▼ 7.29% CSAN3 3.08 ▼ 1.60% RAIZ4 15.00 ▼ 10.71% PCAR3 3.23 ▲ 8.03% GMAT3 4.18 ▲ 3.21% PSSA3 43.96 ▼ 1.57% CVCB3 0.72 ▼ 7.69% POSI3 3.37 ▲ 6.31% SLCE3 17.53 ▼ 1.96% NATU3 4.48 ▼ 6.28% BRKM5 2.60 ▼ 1.14% RANI3 8.01 ▼ 0.74% IBOV 166,376.43 ▼ 0.69% COLCAP 2,452.46 — — IPC MEX 68,713.60 ▼ 0.64% MERVAL 2,848,945 — — USD/BRL 5.94 ▲ 0.01% USD/MXN 19.06 ▼ 0.13% USD/CLP 1,016 ▼ 0.09% USD/COP 3,428 ▲ 2.10% USD/PEN 3.45 ▲ 0.17% USD/ARS 1,565 ▲ 0.01% USD/UYU 40.61 ▲ 3.16% USD/PYG 6,212 ▲ 2.34% USD/BOB 11.64 ▲ 3.02% USD/DOP 59.52 ▼ 0.80% USD/CRC 441.73 ▲ 2.68% USD/GTQ 7.64 ▲ 3.23% USD/HNL 26.89 ▲ 3.31% USD/NIO 36.62 ▲ 0.34% USD/VES 913.46 ▼ 0.45% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.59 ▲ 2.60% USD/TTD 6.70 ▲ 2.00% EUR/BRL 6.52 ▲ 1.16% BRENT 89.48 ▼ 2.72% WTI 82.44 ▼ 0.93% IRON ORE 161.91 — — COPPER 5.54 ▼ 1.56% GOLD 3,576 ▼ 2.97% SILVER 42.21 ▼ 4.76% SOY 1,213 ▲ 0.41% CORN 450.75 ▲ 2.68% WHEAT 596.00 ▲ 3.07% COFFEE 271.80 ▼ 3.63% SUGAR 16.99 ▼ 0.99% ORANGE JUICE 131.95 ▲ 1.85% COTTON 79.55 ▲ 4.74% COCOA 5,230 ▲ 3.30% BEEF 223.00 ▲ 1.47% CATTLE 335.85 ▼ 0.34% LITHIUM 54.33 ▼ 2.23% PETR4 42.67 ▼ 1.16% VALE3 58.48 ▼ 0.88% ITUB4 40.07 ▼ 0.30% BBDC4 13.83 ▼ 1.78% ABEV3 16.08 ▲ 0.06% BBAS3 14.30 ▲ 1.27% B3SA3 14.28 ▼ 0.14% WEGE3 51.13 ▼ 0.49% PRIO3 60.20 ▼ 2.70% SUZB3 55.32 ▼ 0.50% RENT3 28.86 ▼ 2.00% AZZA3 14.63 ▼ 7.29% CSAN3 3.08 ▼ 1.60% RAIZ4 15.00 ▼ 10.71% PCAR3 3.23 ▲ 8.03% GMAT3 4.18 ▲ 3.21% PSSA3 43.96 ▼ 1.57% CVCB3 0.72 ▼ 7.69% POSI3 3.37 ▲ 6.31% SLCE3 17.53 ▼ 1.96% NATU3 4.48 ▼ 6.28% BRKM5 2.60 ▼ 1.14% RANI3 8.01 ▼ 0.74%
since 2009
Friday, November 20, 2026

Covid-19 Brazil

Brazil Diplomatic Push to Guarantee Shipment of India-Made AstraZeneca Vaccine

By · · 3 min read
Brazil made a diplomatic push on Monday, January 4th, to guarantee an Indian-made shipment of British drugmaker AstraZeneca's COVID-19 vaccine, hoping to avoid export restrictions that could delay immunizations during the world's second-deadliest outbreak.
Brazil made a diplomatic push on Monday, January 4th, to guarantee an Indian-made shipment of British drugmaker AstraZeneca’s COVID-19 vaccine, hoping to avoid export restrictions that could delay immunizations during the world’s second-deadliest outbreak.

RIO DE JANEIRO, BRAZIL – Brazil made a diplomatic push on Monday, January 4th, to guarantee shipment of an Indian-made Covid-19 vaccine of British drugmaker AstraZeneca, hoping to avoid export restrictions that could delay immunizations in the country with the world’s second-deadliest outbreak.

In parallel, Brazil’s private clinics struck a preliminary deal for an alternative injection made by India’s Bharat Biotech, despite a lack of published results from late-stage trials.

RT
Ask Rio Times
This story and the bigger picture.
Open the full Ask Rio Times →

The scramble by Brazil’s government and private sector underscored how Latin America’s largest nation, once an example of mass immunization success in the developing world, has fallen behind peers in the race to inoculate against the coronavirus.

Plans by Brazil’s Fiocruz Institute to import AstraZeneca’s vaccine in bulk, filling and finishing doses locally, would only have 1 million doses ready by the second week of February, the head of the government-funded biomedical center revealed.

Amid rising criticism of its slow response and a death toll approaching 200,000, second only to the United States, Brazil is now rushing to import finished doses, playing catch-up to neighboring Chile and Argentina where inoculations are underway.

However, the chief executive of the Serum Institute of India said on Sunday that he expected India’s government to restrict export of COVID-19 vaccines.

That raised red flags in Brasilia, where health regulator Anvisa had granted approval on New Year’s Eve to import 2 million doses of the AstraZeneca vaccine from India. Allegedly diplomats were working to confirm the shipment would not be affected by any export ban. Fiocruz confirmed that Brazil’s Foreign Ministry was leading the talks.

Separately, an association of private Brazilian clinics announced plans to buy 5 million doses of a vaccine developed by Indian company Bharat Biotech, a day after India’s health regulator gave it emergency use approval.

Bharat Biotech has not yet applied for approval by Brazil’s health regulator Anvisa for its Covaxin vaccine, and the agency said it would have to undergo Phase III trials in the country.

Geraldo Barbosa, head of the Brazilian Association of Vaccine Clinics (ABCVAC), who will lead a delegation to India, said a memorandum of understanding has already been signed with Bharat Biotech.

“This should be the first vaccine available on the private market in Brazil,” he said, adding that the Covaxin doses should arrive in Brazil in mid-March, to be sold by private clinics after regulators approve the vaccine.

Anvisa said in a statement on Sunday that Covaxin does not fit into the continuous data submission process for vaccine registration and the vaccine would have to undergo late phase clinical trials in Brazil.

On Sunday, India’s drugs regulator DCGI approved Covaxin and AstraZeneca’s vaccine for emergency use, the first approvals of vaccines in India.

The fast tracking of the homegrown Bharat Biotech vaccine faced questions from industry experts and opposition lawmakers because the company has not published efficacy data.

Covaxin is undergoing late stage trials in the largest such trial in India. A spokeswoman for Bharat Biotech said 24,000 volunteers have been recruited out of a target of 26,000 for the Phase III trial, which began in November.

The pharmaceutical company, based in Hyderabad in southern India, produces millions of doses of vaccines for hepatitis, Zika, Japanese encephalitis and others illnesses.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.